Subtype and pathway specific responses to anticancer compounds in breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 2724-2729

  Heiser, Laura M ^a   Sadanandam, Anguraj ^a,m   Kuo, Wen Lin ^a   Benz, Stephen C ^b   Goldstein, Theodore C ^b   Ng, Sam ^b   Gibb, William J ^a   Wang, Nicholas J ^a   Ziyad, Safiyyah ^a   Tong, Frances ^c   Bayani, Nora ^a   Hu, Zhi ^a   Billig, Jessica I ^a   Dueregger, Andrea ^a   Lewis, Sophia ^a   Jakkula, Lakshmi ^a   Korkola, James E ^a   Durinck, Steffen ^a   Pepin, Franco̧is ^a   Guan, Yinghui ^a   Purdom, Elizabeth ^c   Neuvial, Pierre ^c,n   Bengtsson, Henrik ^a,o   Wood, Kenneth W ^d   Smith, Peter G ^e   Vassilev, Lyubomir T ^f   Hennessy, Bryan T ^g   Greshock, Joel ^h   Bachman, Kurtis E ^h   Hardwicke, Mary Ann ^h   Park, John W ⁱ   Marton, Laurence J ^j   Wolf, Denise M ^a   Collisson, Eric A ⁱ   Neve, Richard M ^a   Mills, Gordon B ^g   Speed, Terence P ^c,k   Feiler, Heidi S ^a   Richard, F Wooster ^h   Haussler, David ^b,l   Stuart, Joshua M ^b   Gray, Joe W ^a,p   Spellman, Paul T ^a,q   more..

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b University of California Santa Cruz   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Cytokinetics Inc   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Progen Pharmaceuticals   (United States)

^k WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m EPFL   (Switzerland)

ⁿ UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p Oregon Health and Science University Department of Biomedical Engineering   (United States)

^q OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

Genomics; Predictor; Therapeutics

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AFATINIB; ANTINEOPLASTIC AGENT; AURORA A KINASE; CARBOPLATIN; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; FASCAPLYSIN; GEFITINIB; GSK 1070916; LAPATINIB; METHOTREXATE; ONCOPROTEIN; PANOBINOSTAT; PEMETREXED; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; TANESPIMYCIN; TEMSIROLIMUS; TOZASERTIB; TRICHOSTATIN A; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CELL TYPE; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC TRANSCRIPTION; PHARMACOGENOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE DOSAGE; HUMANS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84863115693     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018854108     Document Type: Article

References (37)

1. Anonymous (2010) New Medicines Database | PHRMA. Available at http://newmeds. phrma.org/. Accessed September, 2011.
2. Sawyers C (2004) Targeted cancer therapy. Nature 432:294-297.
3. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500. (Pubitemid 38720929)
4. Neve RM, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527. (Pubitemid 44854747)
5. Konecny GE, et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639. (Pubitemid 43259947)
6. Scappini B, et al. (2004) Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 100:1459-1471. (Pubitemid 38366849)
7. Weinstein JN (2006) Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 5:2601-2605.
8. Hennessy BT, et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116-4124.
9. Herschkowitz JI, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol, 8: R76; 1-17.
10. Carey LA, et al. (2007) The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334. (Pubitemid 46698581)
11. Silver DP, et al. (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153.
12. Hardwicke MA, et al. (2009) GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 8:1808-1817.
13. Nakashima T, et al. (2005) The effect of cyclin D1 overexpression in human head and neck cancer cells. Eur Arch Otorhinolaryngol 262:379-383. (Pubitemid 40768600)
14. Huerta S, et al. (2003) Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 22:663-670.
15. Yu D, et al. (1998) Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2:581-591.
16. Tan M, et al. (2002) Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34 (Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9: 993-1004. (Pubitemid 34626669)
17. Vaske CJ, et al. (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26:i237-i245.
18. Kristensen VN, et al. (2012) Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA 109:2802-2807.
19. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310. (Pubitemid 46763022)
20. Hynes NE, Stoelzle T (2009) Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res 11:210-219.
21. Bhoumik A, Jones N, Ronai Z (2004) Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci USA 101:4222-4227. (Pubitemid 38405910)
22. Habashy HO, et al. (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44:1541-1551.
23. Badve S, et al. (2007) FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clin Cancer Res 13:4415-4421. (Pubitemid 47219708)
24. Michaelson JS, Leder P (2001) beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 20:5093-5099. (Pubitemid 32844037)
25. Lin SY, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97:4262-4266.
26. Siddik ZH (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279. (Pubitemid 37487159)
27. Blagosklonny MV (2002) Hsp-90-associated oncoproteins: Multiple targets of geldanamycin and its analogs. Leukemia 16:455-462.
28. Baselga J, Swain SM (2009) Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475.
29. Kuo WL, et al. (2009) A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med 7:77-88.
30. National Cancer Institute (2011) Screening Services - NCI-60 DTP Human Tumor Cell Line Screen. Available at http://dtp.nci.nih.gov/branches/btb/ivclsp. html. Accessed September 2011.
31. Monks A, et al. (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766.
32. Bengtsson H, Irizarry R, Carvalho B, Speed TP (2008) Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics 24:759-767. (Pubitemid 351386913)
33. Bengtsson H, Wirapati P, Speed TP (2009) A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including Genome Wide SNP 5 & 6. Bioinformatics 25:2149-2156.
34. Venkatraman ES, Olshen AB (2007) A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23:657-663. (Pubitemid 46554715)
35. Beroukhim R, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci USA 104: 20007-20012.
36. Monti S, Tamayo P, Mesirov JP, Golub TA (2003) Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn 52:91-118.
37. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121. (Pubitemid 32397092)